Thursday, June 11, 2026
🇺🇸 FDA

pharma · Atherosclerosis · Non-small Cell Lung Cancer (NSCLC)

MSD Merck Sharp

Merck Sharp and Dohme

MSD Merck Sharp clinical programs — 217 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
WERFTESTRASSE 4, Lucerne, 6005, ch HQ
61 Employees
EMA registrant Type
Company details
Status
Public
HQ
WERFTESTRASSE 4, Lucerne, 6005, ch
Employees
61
Programs
217
Drugs
180
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

MSD Merck Sharp projects

217 ClinicalTrials.gov programs sponsored by MSD Merck Sharp.

MSD Merck Sharp has 217 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

217 programs

Clinical programs

Page 4 of 5

  1. MK-7962-023

    Merck Sharp and Dohme

    Pulmonary Hypertension

    phase 2 small molecule active

    1 trial

  2. MK-7962-024

    Merck Sharp and Dohme

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule active

    1 trial

  3. MK-7962-031

    Merck Sharp and Dohme

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule active

    1 trial

  4. MK-8591-013

    Merck Sharp and Dohme

    HIV-1 Infection

    phase 2 small molecule active

    1 trial

  5. MK-9999-01C

    Merck Sharp and Dohme

    Hepatoblastoma, Rhabdomyosarcoma

    phase 2 small molecule active

    1 trial

  6. MK-9999-02A

    Merck Sharp and Dohme

    Colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  7. MS200095-0031

    Merck Sharp and Dohme

    Lung Cancer

    phase 2 small molecule active

    1 trial

  8. MS200569_0003

    Merck Sharp and Dohme

    Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)

    phase 2 small molecule active

    1 trial

  9. MS201924_0002

    Merck Sharp and Dohme

    Epithelial ovarian cancer that progressed on prior PARP inhibitor therapy

    phase 2 small molecule active

    1 trial

  10. MS201924_0022

    Merck Sharp and Dohme

    Non-Squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  11. Placebo for MK-7240, tulisokibart

    Merck Sharp and Dohme

    Radiographic axial spondyloarthritis (as known as ankylosing spondylitis)

    phase 2 small molecule active

    1 trial

  12. Placebo to MK-6194, MK-6194

    Merck Sharp and Dohme

    Non segmental vitiligo

    phase 2 small molecule active

    1 trial

  13. SOTATERCEPT, sotatercept

    Merck Sharp and Dohme

    Pulmonary arterial hypertension

    phase 2 small molecule active

    1 trial

  14. Tepotinib

    Merck Sharp and Dohme

    Lung Cancer

    phase 2 small molecule active

    1 trial

  15. V940-004

    Merck Sharp and Dohme

    Intermediate-high -risk RCC, high-risk RCC who have undergone nephrectomy, or M1 NED RCC who have undergone nephrectomy and metastasectomy.

    phase 2 small molecule active

    1 trial

  16. V940-005

    Merck Sharp and Dohme

    Muscle-invasive Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  17. V940-012

    Merck Sharp and Dohme

    Melanoma

    phase 2 small molecule active

    1 trial

  18. V940-013

    Merck Sharp and Dohme

    Non-small cell lung cancer stage IV

    phase 2 small molecule active

    1 trial

  19. Zilovertamab vedotin

    Merck Sharp and Dohme

    Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults

    phase 2 small molecule active

    1 trial

  20. mRNA-4157, BCG VACCINE

    Merck Sharp and Dohme

    Bladder cancer

    phase 2 small molecule active

    1 trial

  21. tulisokibart, Placebo to MK-7240

    Merck Sharp and Dohme

    Psoriatic arthritis​​

    phase 2 small molecule active

    1 trial

  22. tulisokibart, Placebo to MK-7240 (tulisokibart)

    Merck Sharp and Dohme

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  23. A Multiple-Ascending-Dose Study of MK-1708 in Healthy Participants

    Merck Sharp and Dohme

    Amyotrophic lateral sclerosis and Alzheimer’s disease

    phase 1 other active

    1 trial

  24. A Single-Ascending-Dose Study of MK6916 in Healthy Participants

    Merck Sharp and Dohme

    Acute and chronic Pain

    phase 1 other active

    1 trial

  25. A clinical study of MK-0472 in people with solid tumors (MK-0472-001)

    Merck Sharp and Dohme

    Malignant Neoplasm - Solid Tumors

    phase 1 other active

    1 trial

  26. A clinical study of MK-1289 in healthy adult men (MK-1289-001)

    Merck Sharp and Dohme

    COVID-19 Infection

    phase 1 other active

    1 trial

  27. A clinical study of MK-1403 in healthy men (MK-1403-004)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  28. A clinical study of MK-1403 in healthy people (MK-1403-002)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  29. A clinical study of MK-2420 in healthy men (MK-2420-003)

    Merck Sharp and Dohme

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  30. A clinical study of MK-2420 in healthy people (MK-2420-002)

    Merck Sharp and Dohme

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  31. A clinical study of MK-2828 in healthy people (MK-2828-001)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  32. A clinical study of MK-2828 in healthy people (MK-2828-002)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  33. A clinical study of MK-3214 in healthy people (MK-3214-001)

    Merck Sharp and Dohme

    Hypercholesterolaemia

    phase 1 other active

    1 trial

  34. A clinical study of MK-3508 in healthy people (MK-3508-006)

    Merck Sharp and Dohme

    Respiratory syncytial virus infection

    phase 1 other active

    1 trial

  35. A clinical study of MK-4082 in healthy people (MK-4082-001)

    Merck Sharp and Dohme

    Weight management

    phase 1 other active

    1 trial

  36. A clinical study of MK-4646 in healthy people (MK-4646-002)

    Merck Sharp and Dohme

    HIV infection

    phase 1 other active

    1 trial

  37. A clinical study of MK-4646 in people with HIV (MK-4646-003)

    Merck Sharp and Dohme

    HIV infection

    phase 1 other active

    1 trial

  38. A clinical study of MK-5661 and placebo in healthy people (MK-5661-006)

    Merck Sharp and Dohme

    Pain

    phase 1 other active

    1 trial

  39. A clinical study of MK-5661 in healthy people (MK-5661-007)

    Merck Sharp and Dohme

    Pain

    phase 1 other active

    1 trial

  40. A clinical study of MK-6050 in healthy people (MK-6050-001)

    Merck Sharp and Dohme

    Hidradenitis suppurativa

    phase 1 other active

    1 trial

  41. A clinical study of MK-6916 and placebo in healthy people (MK-6916-003)

    Merck Sharp and Dohme

    Acute and chronic Pain

    phase 1 other active

    1 trial

  42. A clinical study of MK-6916 in healthy people (MK-6916-002)

    Merck Sharp and Dohme

    Acute and Chronic Pain

    phase 1 other active

    1 trial

  43. A clinical study of MK-6916 in healthy people (MK-6916-006)

    Merck Sharp and Dohme

    Acute and chronic Pain

    phase 1 other active

    1 trial

  44. A clinical study of MK-7228 in healthy men (MK-7228-001)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  45. A clinical study of the V540A vaccine in healthy adults (V540A-001)

    Merck Sharp and Dohme

    Human Papilloma virus

    phase 1 other active

    1 trial

  46. A clinical study of the V540C vaccine in healthy adults (V540C-003)

    Merck Sharp and Dohme

    Human Papilloma virus

    phase 1 other active

    1 trial

  47. A clinical trial of MK-1824 in healthy participants (MK-1824-001)

    Merck Sharp and Dohme

    Heart failure with preserved ejection fraction

    phase 1 other active

    1 trial

  48. A clinical trial of MK-4605 in healthy participants (MK-4605-001)

    Merck Sharp and Dohme

    Dementia

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does MSD Merck Sharp have?

217 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.